Publication In PNAS Utilizes Invitrogen's ProtoArray(R) Technology to Discover Novel Candidate Ovarian Cancer Biomarkers.CARLSBAD, Calif. -- Invitrogen Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the publication of a study in the journal of Proceedings of National Academy of Sciences (PNAS PNAS Proceedings of the National Academy of Sciences PNAS Phosphate:Na + Symporter PNAS Pensacola Naval Air Station PNAS Philippine National Airsoft Society ) that applies the company's ProtoArray([R]) technology to identify new autoantigens associated with ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast . Ovarian cancer is the fifth leading cause of cancer deaths among women and is very difficult to detect before it spreads to adjacent tissues and organs. "Invitrogen is at the forefront of companies powering advances that promise to change healthcare," noted Kip Miller Kip Charles Miller (born June 11, 1969 in Lansing, Michigan) is an American ice hockey forward, currently playing for the American Hockey League Grand Rapids Griffins. He was drafted by the Quebec Nordiques as their 4th-round pick in the 1987 NHL Entry Draft, 72nd overall. , Senior Vice President, Biodiscovery of Invitrogen. "A clear need exists to find biological markers that indicate the presence of ovarian cancer, and we are especially pleased to be involved in this groundbreaking science. Such research may serve as the foundation for developing a reliable diagnostic for identifying ovarian cancer before it starts to spread." In the experiments documented in the PNAS paper, sera samples from 30 ovarian cancer patients and 30 healthy subjects were profiled on the ProtoArray([R]) protein microarrays. From this data, scientists identified over 94 candidate biomarkers that exhibited enhanced reactivity in sera from cancer patients compared to the sera of healthy subjects. Subsequent experiments on a subset of those proteins designed to validate the results achieved with the ProtoArray([R]) showed an increase in expression of those proteins in tissue samples of ovarian cancer patients compared to healthy subjects. The results of this study were published in an article entitled "Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays" (Michael Hudson et. al.; PNAS; October, 2007). "Not only are autoantibodies well-known biomarkers in autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause such as lupus lupus (l  `pəs), noninfectious chronic disease in which antibodies in an individual's immune system attack the body's own substances. or multiple sclerosis, but they have
been shown in a range of cancers," said Paul Predki, Invitrogen
Vice President of Protein Analysis R&D. "Protein microarrays
provide a rapid and sensitive platform for the screening of
autoantibodies. This study validates the ProtoArray([R]) as a powerful
technology that scientists can use to discover new markers that indicate
whether a patient has a disease or shows how a disease may have
progressed."
The ProtoArray([R]) protein microarray utilizes high density placement of proteins on a glass slide, allowing the study of over 8,000 unique human proteins on the array in a single experiment. In addition to biomarker discovery Biomarker discovery is the process by which biomarkers are discovered. It is a medical term. Many commonly used blood tests in medicine are biomarkers. The way that these tests have been found can be seen as biomarker discovery. , the ProtoArray([R]) technology enables a broad range of applications, including kinase substrate identification, protein-protein interaction Protein-protein interactions refer to the association of protein molecules and the study of these associations from the perspective of biochemistry, signal transduction and networks. The interactions between proteins are important for many biological functions. mapping, antibody specificity profiling, and small molecule specificity testing. About Invitrogen Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics Noun 1. functional genomics - the branch of genomics that determines the biological function of the genes and their products genomics - the branch of genetics that studies organisms in terms of their genomes (their full DNA sequences) , proteomics, bioinformatics and cell biology Cell biology The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented. -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company is celebrating 20 years of accelerating scientific discovery. Invitrogen globally employs approximately 4,300 scientists and other professionals and had revenues of more than $1.15 billion in 2006. For more information, visit www.invitrogen.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) The ProtoArray([R]) is a powerful technology that scientists can use to discover new markers that indicate whether a patient has a disease or shows how a disease may have progressed. Potential risks and uncertainties include, but are not limited to: a) The ProtoArray([R] )may or may not help develop a reliable diagnostic for identifying ovarian cancer, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion